Tofogliflozin

Source: Wikipedia, the free encyclopedia.
Tofogliflozin monohydrate
Clinical data
Other namesCSG452
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • (1S,3'R,4'S,5'S,6'R)-6-(4-Ethylbenzyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3H-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol hydrate (1:1)
JSmol)
  • CCc1ccc(cc1)Cc2ccc3c(c2)[C@]4([C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC3.O
  • InChI=1S/C22H26O6.H2O/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22;/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3;1H2/t18-,19-,20+,21-,22+;/m1./s1
  • Key:ZXOCGDDVNPDRIW-NHFZGCSJSA-N

Tofogliflozin (

SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. As of September 2012, the drug is in Phase III clinical trials.[3][4][needs update
]

Chemistry

Anhydrous tofogliflozin

The active moiety or

CHEMBL2110731) has the chemical formula C22H26O6 and a molecular mass
of 386.44 g/mol.

The

International Nonproprietary Name tofogliflozin applies to the anhydrous compound[1]
and the drug form is referred to as tofogliflozin hydrate.

See also

  • Gliflozin

References

  1. ^ a b "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. Retrieved 15 November 2016.
  2. ^ Chugai Pharmaceutical: Development Pipeline
  3. PMID 23249697
    .
  4. PMID 22889351
    .
  5. ^ Statement on a nonproprietary name adopted by the USAN council: Tofogliflozin.
gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tofogliflozin&oldid=1187855221"